Robert J Levy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10698454/publications.pdf

Version: 2024-02-01

179 papers	10,766 citations	36299 51 h-index	34984 98 g-index
184 all docs	184 docs citations	184 times ranked	8603 citing authors

#	Article	IF	Citations
1	Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharmaceutical Research, 1996, 13, 1838-1845.	3.5	819
2	The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharmaceutical Research, 1997, 14, 1568-1573.	3.5	753
3	Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and Prevention. Annals of Thoracic Surgery, 2005, 79, 1072-1080.	1.3	608
4	Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles. Journal of Controlled Release, 2003, 92, 173-187.	9.9	446
5	Tissue heart valves: Current challenges and future research perspectives. Journal of Biomedical Materials Research Part B, 1999, 47, 439-465.	3.1	396
6	Progression of aortic valve stenosis: TGF-Î²1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Annals of Thoracic Surgery, 2003, 75, 457-465.	1.3	387
7	High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 698-703.	7.1	239
8	Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nature Biotechnology, 2000, 18, 1181-1184.	17.5	223
9	Prevention of Bioprosthetic Heart Valve Calcification by Ethanol Preincubation. Circulation, 1997, 95, 479-488.	1.6	216
10	Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8346-8351.	7.1	181
11	Serotonin Mechanisms in Heart Valve Disease I. American Journal of Pathology, 2002, 161, 2111-2121.	3.8	168
12	Matrix Metalloproteinase-2 Is Associated with Tenascin-C in Calcific Aortic Stenosis. American Journal of Pathology, 2001, 159, 321-327.	3.8	162
13	Arterial Uptake of Biodegradable Nanoparticles: Effect of Surface Modifications. Journal of Pharmaceutical Sciences, 1998, 87, 1229-1234.	3.3	160
14	Use of Hancock porcine xenografts in children and adolescents. American Journal of Cardiology, 1980, 46, 429-438.	1.6	148
15	Nanoparticle drug delivery system for restenosis. Advanced Drug Delivery Reviews, 1997, 24, 63-85.	13.7	139
16	Transforming Growth Factor-Î²1 Mechanisms in Aortic Valve Calcification: Increased Alkaline Phosphatase and Related Events. Annals of Thoracic Surgery, 2007, 83, 946-953.	1.3	135
17	Mechanisms of bioprosthetic heart valve failure: Fatigue causes collagen denaturation and glycosaminoglycan loss. Journal of Biomedical Materials Research Part B, 1999, 46, 44-50.	3.1	125
18	Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog model. Journal of Controlled Release, 1998, 54, 201-211.	9.9	123

#	Article	IF	Citations
19	In-Vivo Dynamic Deformation of the Mitral Valve Anterior Leaflet. Annals of Thoracic Surgery, 2006, 82, 1369-1377.	1.3	122
20	Pathological considerations in replacement cardiac valves. Cardiovascular Pathology, 1992, 1, 29-52.	1.6	116
21	Effects of Antisense c- myb Oligonucleotides on Vascular Smooth Muscle Cell Proliferation and Response to Vessel Wall Injury. Circulation Research, 1995, 76, 505-513.	4.5	112
22	Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles. FASEB Journal, 2007, 21, 2510-2519.	0.5	111
23	Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. Journal of Controlled Release, 2010, 146, 144-151.	9.9	104
24	Serotonin Mechanisms in Heart Valve Disease II. American Journal of Pathology, 2002, 161, 2209-2218.	3.8	101
25	Bioprosthetic Heart Valve Failure: Pathology and Pathogenesis. Cardiology Clinics, 1984, 2, 717-739.	2.2	100
26	Atherocalcin, a Î³-carboxyglutamic acid containing protein from atherosclerotic plaque. Biochemical and Biophysical Research Communications, 1979, 91, 41-49.	2.1	93
27	Elastin Calcification and its Prevention with Aluminum Chloride Pretreatment. American Journal of Pathology, 1999, 155, 973-982.	3.8	92
28	Gene Delivery to Pig Coronary Arteries from Stents Carrying Antibody-Tethered Adenovirus. Human Gene Therapy, 2002, 13, 443-454.	2.7	92
29	Gene therapy for tissue repair and regeneration. Advanced Drug Delivery Reviews, 1998, 33, 53-69.	13.7	91
30	Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 159-164.	7.1	91
31	Calcification of cardiac valve bioprostheses. Journal of Thoracic and Cardiovascular Surgery, 1982, 83, 602-609.	0.8	86
32	Onset and progression of calcification in porcine aortic bioprosthetic valves Implanted as orthotopic mitral valve replacements in juvenile sheep. Journal of Thoracic and Cardiovascular Surgery, 1994, 108, 880-887.	0.8	82
33	Triglycidylamine Crosslinking of Porcine Aortic Valve Cusps or Bovine Pericardium Results in Improved Biocompatibility, Biomechanics, and Calcification Resistance. American Journal of Pathology, 2005, 166, 1-13.	3.8	80
34	Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. Biomaterials, 2014, 35, 3708-3715.	11.4	80
35	Inhibition of Matrix Metalloproteinase Activity Attenuates Tenascin-C Production and Calcification of Implanted Purified Elastin in Rats. American Journal of Pathology, 2000, 157, 885-893.	3.8	78
36	Initiation of mineralization in bioprosthetic heart valves: Studies of alkaline phosphatase activity and its inhibition by AlCl3 or FeCl3 preincubations. Journal of Biomedical Materials Research Part B, 1991, 25, 905-935.	3.1	77

#	Article	IF	Citations
37	A DNA Controlled-Release Coating for Gene Transfer: Transfection in Skeletal and Cardiac Muscle. Journal of Pharmaceutical Sciences, 1998, 87, 1347-1350.	3.3	77
38	Delivery and expression of pDNA embedded in collagen matrices. Journal of Controlled Release, 2004, 95, 309-320.	9.9	77
39	Mechanism of calcification of porcine bioprosthetic aortic valve cusps: Role of T-lymphocytes. American Journal of Cardiology, 1983, 52, 629-631.	1.6	73
40	Cardiovascular implant calcification: a survey and update. Biomaterials, 1991, 12, 707-714.	11.4	72
41	Pathology of Substitute Heart Valves: New Concepts and Developments. Journal of Cardiac Surgery, 1994, 9, 222-227.	0.7	72
42	The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation. Biomaterials, 2011, 32, 4317-4326.	11.4	71
43	Vitamin K-dependent Calcium Binding Proteins in Aortic Valve Calcification. Journal of Clinical Investigation, 1980, 65, 563-566.	8.2	70
44	Controlled-Release Drug Delivery of Diphosphonates to Inhibit Bioprosthetic Heart Valve Calcification: Release Rate Modulation with Silicone Matrices Via Drug Solubility and Membrane Coating. Journal of Pharmaceutical Sciences, 1987, 76, 271-276.	3.3	69
45	Local Delivery of Gene Vectors From Bare-Metal Stents by Use of a Biodegradable Synthetic Complex Inhibits In-Stent Restenosis in Rat Carotid Arteries. Circulation, 2008, 117, 2096-2103.	1.6	68
46	Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: Mechanistic studies of protein structure and water-biomaterial relationships. , 1998, 40, 577-585.		65
47	Gene transfection using biodegradable nanospheres: results in tissue culture and a rat osteotomy model. Colloids and Surfaces B: Biointerfaces, 1999, 16, 281-290.	5.0	59
48	Sustained behavioral recovery from unilateral nigrostriatal damage produced by the controlled release of dopamine from a silicone polymer pellet placed into the denervated striatum. Brain Research, 1990, 508, 60-64.	2.2	58
49	Antimineralization treatments for bioprosthetic heart valves. Journal of Thoracic and Cardiovascular Surgery, 1992, 104, 1285-1288.	0.8	58
50	Inhibition of calcification of glutaraldehyde pretreated porcine aortic valve cusps with sodium dodecyl sulfate: Preincubation and controlled release studies. Journal of Biomedical Materials Research Part B, 1993, 27, 1477-1484.	3.1	55
51	Inhibition of aortic wall calcification in bioprosthetic heart valves by ethanol pretreatment: Biochemical and biophysical mechanisms. Journal of Biomedical Materials Research Part B, 1998, 42, 30-37.	3.1	52
52	Controlled release of diphosphonate to inhibit bioprosthetic heart valve calcification: Dose-response and mechanistic studies. Journal of Controlled Release, 1986, 4, 181-194.	9.9	51
53	Inhibition of Bioprosthetic Heart Valve Calcification with Aminodiphosphonate Covalently Bound to Residual Aldehyde Groups. Annals of Thoracic Surgery, 1988, 46, 309-316.	1.3	51
54	Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces. Biomaterials, 2012, 33, 5803-5811.	11.4	50

#	Article	IF	Citations
55	Effect of 2-amino oleic acid exposure conditions on the inhibition of calcification of glutaraldehyde cross-linked porcine aortic valves. Journal of Biomedical Materials Research Part B, 1994, 28, 1485-1495.	3.1	49
56	Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercapto bisphosphonate. Biomaterials, 2007, 28, 690-699.	11.4	48
57	Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy. Journal of Thoracic and Cardiovascular Surgery, 1987, 94, 551-557.	0.8	47
58	Calcification and Oxidative Modifications Are Associated With Progressive Bioprosthetic Heart Valve Dysfunction. Journal of the American Heart Association, 2017, 6, .	3.7	46
59	Endovascular Microcoil Gene Delivery Using Immobilized Anti-adenovirus Antibody for Vector Tethering. Stroke, 2002, 33, 1376-1382.	2.0	44
60	Fenfluramine Disrupts the Mitral Valve Interstitial Cell Response to Serotonin. American Journal of Pathology, 2009, 175, 988-997.	3.8	44
61	Epicardial Administration of Ibutilide from Polyurethane Matrices. Journal of Cardiovascular Pharmacology, 1994, 24, 826-840.	1.9	43
62	Aortic Valve Cyclic Stretch Causes Increased Remodeling Activity and Enhanced Serotonin Receptor Responsiveness. Annals of Thoracic Surgery, 2011, 92, 147-153.	1.3	43
63	Prevention of calcification of glutaraldehyde pretreated bovine pericardium through controlled release polymeric implants: studies of Fe3+, Al3+, protamine sulphate and levamisole. Biomaterials, 1990, 11, 718-723.	11.4	42
64	Tissue heart valves: Current challenges and future research perspectives. Journal of Biomedical Materials Research Part B, 1999, 47, 439-465.	3.1	41
65	Inhibition of cusp and aortic wall calcification in ethanol- and aluminum-treated bioprosthetic heart valves in sheep: background, mechanisms, and synergism. Journal of Heart Valve Disease, 2003, 12, 209-16; discussion 216.	0.5	39
66	Current Progress in Anticalcif ication for Bioprosthetic and Polymeric Heart Valves. Cardiovascular Pathology, 1997, 6, 219-229.	1.6	38
67	Prevention of polyurethane valve cusp calcification with covalently attached bisphosphonate diethylamino moieties. Journal of Biomedical Materials Research Part B, 2003, 66A, 385-395.	3.1	38
68	Magnetically Responsive Biodegradable Nanoparticles Enhance Adenoviral Gene Transfer in Cultured Smooth Muscle and Endothelial Cells. Molecular Pharmaceutics, 2009, 6, 1380-1387.	4.6	38
69	The susceptibility of bioprosthetic heart valve leaflets to oxidation. Biomaterials, 2014, 35, 2097-2102.	11.4	38
70	Î³-Carboxyglutamate excretion and warfarin therapy. Clinical Pharmacology and Therapeutics, 1979, 25, 562-570.	4.7	37
71	Porcine Bioprosthetic Valve Calcification in Bovine Left Ventricle-Aorta Shunts: Studies of the Deposition of Vitamin K-Dependent Proteins. Annals of Thoracic Surgery, 1983, 36, 187-192.	1.3	37
72	Serotonin Transporter Mechanisms and Cardiac Disease. Circulation, 2006, 113, 2-4.	1.6	37

#	Article	IF	Citations
73	Enhanced biocompatibility of CD47-functionalized vascular stents. Biomaterials, 2016, 87, 82-92.	11.4	37
74	Capillary Electrophoresis of Supercoiled and Linear DNA in Dilute Hydroxyethyl Cellulose Solution. Analytical Chemistry, 1997, 69, 1192-1196.	6.5	36
75	Refinement of the Alpha Aminooleic Acid Bioprosthetic Valve Anticalcification Technique. Annals of Thoracic Surgery, 1997, 64, 50-58.	1.3	36
76	Cholesterol-Modified Polyurethane Valve Cusps Demonstrate Blood Outgrowth Endothelial Cell Adhesion Post-Seeding In Vitro and In Vivo. Annals of Thoracic Surgery, 2006, 81, 47-55.	1.3	36
77	Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. Biomaterials, 2015, 51, 22-29.	11.4	36
78	Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation. Coronary Artery Disease, 1994, 5, 435-442.	0.7	35
79	A novel mercapto-bisphosphonate as an efficient anticalcification agent for bioprosthetic tissues. Journal of Organometallic Chemistry, 2005, 690, 2543-2547.	1.8	35
80	Covalent binding of aminopropanehydroxydiphosphonate to glutaraldehyde residues in pericardial bioprosthetic tissue: Stability and calcification inhibition studies. Experimental and Molecular Pathology, 1989, 50, 291-302.	2.1	33
81	Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-Î² mechanisms. Cardiovascular Pathology, 2020, 46, 107196.	1.6	33
82	Site specific gene delivery in the cardiovascular system. Journal of Controlled Release, 2005, 109, 37-48.	9.9	32
83	Siteâ€specific gene delivery to stented arteries using magnetically guided zinc oleateâ€based nanoparticles loaded with adenoviral vectors. FASEB Journal, 2013, 27, 2198-2206.	0.5	32
84	Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. Cancer Letters, 2015, 360, 205-212.	7.2	32
85	Growth after Surgical Repair of Simple d-Transposition of the Great Arteries. Annals of Thoracic Surgery, 1978, 25, 225-230.	1.3	30
86	Calcification of valved aortic allografts in rats: Effects of age, crosslinking, and inhibitors. Journal of Biomedical Materials Research Part B, 1995, 29, 217-226.	3.1	30
87	Immobilization of plasmid DNA on an antiâ€DNA antibody modified coronary stent for intravascular siteâ€specific gene therapy. Journal of Gene Medicine, 2008, 10, 421-429.	2.8	30
88	Cholesterol-derivatized polyurethane: Characterization and endothelial cell adhesion. Journal of Biomedical Materials Research - Part A, 2005, 72A, 200-212.	4.0	29
89	Serotonin and catecholamines in the development and progression of heart valve diseases. Cardiovascular Research, 2017, 113, 849-857.	3.8	29
90	Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation. Journal of Molecular and Cellular Cardiology, 2018, 115, 94-103.	1.9	29

#	Article	IF	Citations
91	Noncalcific Mechanisms of Bioprosthetic Structural Valve Degeneration. Journal of the American Heart Association, 2021, 10, e018921.	3.7	29
92	The Incorporation of an Ion Channel Gene Mutation Associated with the Long QT Syndrome (Q9E-hMiRP1) in a Plasmid Vector for Site-Specific Arrhythmia Gene Therapy: In Vitro and In Vivo Feasibility Studies. Human Gene Therapy, 2003, 14, 907-922.	2.7	28
93	Effects of metallic ions and diphosphonates on inhibition of pericardial bioprosthetic tissue calcification and associated alkaline phosphatase activity. Biomaterials, 1993, 14, 371-377.	11.4	27
94	Sotalol Controlled-Release Systems for Arrhythmias: In Vitro Characterization, in Vivo Drug Disposition, and Electrophysiologic Effects. Journal of Pharmaceutical Sciences, 1994, 83, 156-164.	3.3	27
95	Calcification of polyurethanes implanted subdermally in rats is enhanced by calciphylaxis. , 1996, 31, 201-207.		27
96	Adenoviral Gene Vector Tethering to Nanoparticle Surfaces Results in Receptor-Independent Cell Entry and Increased Transgene Expression. Molecular Therapy, 2006, 14, 382-391.	8.2	27
97	Triglycidyl Amine Crosslinking Combined With Ethanol Inhibits Bioprosthetic Heart Valve Calcification. Annals of Thoracic Surgery, 2011, 92, 858-865.	1.3	27
98	Magnetically enhanced cell delivery for accelerating recovery of the endothelium in injured arteries. Journal of Controlled Release, 2016, 222, 169-175.	9.9	27
99	Calcification resistance with aluminum-ethanol treated porcine aortic valve bioprostheses in juvenile sheep. Annals of Thoracic Surgery, 2003, 75, 1267-1273.	1.3	26
100	Prevention of Calcification of Bioprosthetic heart Valve Leaflets by Ca2+ Diphosphonate Pretreatment. Journal of Pharmaceutical Sciences, 1988, 77, 740-744.	3.3	24
101	Cardiac controlled release for arrhythmia therapy: Lidocaine-polyurethane matrix studies. Journal of Controlled Release, 1988, 8, 157-165.	9.9	24
102	Posttranslational Control of a Cardiac Ion Channel Transgene In Vivo: Clarithromycinâ€“hMiRP1-Q9E Interactions. Human Gene Therapy, 2005, 16, 906-910.	2.7	24
103	Phosphonated polyurethanes that resist calcification. Journal of Applied Biomaterials: an Official Journal of the Society for Biomaterials, 1994, 5, 65-77.	1.2	23
104	Formulation and In Vitro Characterization of Composite Biodegradable Magnetic Nanoparticles for Magnetically Guided Cell Delivery. Pharmaceutical Research, 2012, 29, 1232-1241.	3.5	23
105	Addressing the Inflammatory Response to Clinically Relevant Polymers by Manipulating the Host Response Using ITIM Domain-Containing Receptors. Polymers, 2014, 6, 2526-2551.	4.5	22
106	The use of CD47-modified biomaterials to mitigate the immune response. Experimental Biology and Medicine, 2016, 241, 1033-1041.	2.4	22
107	Age-related enhanced degeneration of bioprosthetic valves due to leaflet calcification, tissue crosslinking, and structural changes. Cardiovascular Research, 2023, 119, 302-315.	3.8	22
108	Modulated drug release using iontophoresis through heterogeneous cation exchange membranes: membrane preparation and influence of resin crosslinkage. Macromolecules, 1992, 25, 2531-2540.	4.8	21

#	Article	IF	Citations
109	Elastomeric polyurethanes modified with geminal bisphosphonate groups. Journal of Polymer Science Part A, 2001, 39, 105-116.	2.3	21
110	In vivo biomechanical assessment of triglycidylamine crosslinked pericardium. Biomaterials, 2007, 28, 5390-5398.	11.4	21
111	Birthweight of Infants With Congenital Heart Disease. JAMA Pediatrics, 1978, 132, 249.	3.0	20
112	Controlled release implants for cardiovascular disease. Journal of Controlled Release, 1990, 11, 245-254.	9.9	20
113	The effect of intramural delivery of polymeric nanoparticles loaded with the antiproliferative 2-aminochromone U-86983 on neointimal hyperplasia development in balloon-injured porcine coronary arteries. Advanced Drug Delivery Reviews, 1997, 24, 87-108.	13.7	20
114	Prevention of oxidative degradation of polyurethane by covalent attachment of diâ€•tert â€butylphenol residues. Journal of Biomedical Materials Research - Part A, 2006, 78A, 653-661.	4.0	20
115	Real-time analysis of composite magnetic nanoparticle disassembly in vascular cells and biomimetic media. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4245-4250.	7.1	20
116	Modulation of NO and ROS production by AdiNOS transduced vascular cells through supplementation with L-Arg and BH4: Implications for gene therapy of restenosis. Atherosclerosis, 2013, 230, 23-32.	0.8	19
117	Glycation and Serum Albumin Infiltration Contribute to the Structural Degeneration of Bioprosthetic Heart Valves. JACC Basic To Translational Science, 2020, 5, 755-766.	4.1	19
118	Retardation of calcification of bovine pericardium used in bioprosthetic heart valves by phosphocitrate and a synthetic analogue. Biomaterials, 1988, 9, 393-397.	11.4	18
119	Synergistic inhibition of the calcification of glutaraldehyde pretreated bovine pericardium in a rat subdermal model by FeCl3 and ethanehydroxydiphosphonate: pre-incubation and polymeric controlled release studies. Biomaterials, 1993, 14, 705-711.	11.4	18
120	Differential calcification of cusps and aortic wall of failed stented porcine bioprosthetic valves. , 1997, 34, 411-415.		18
121	Prevention of Calcification of Bioprosthetic Heart Valve Cusp and Aortic Wall With Ethanol and Aluminum Chloride. Annals of Thoracic Surgery, 2005, 79, 897-904.	1.3	18
122	Inhibition of Bioprosthetic Heart Valve Calcification by Sustained Local Delivery of Ca and Na Diphosphonate via Controlled Release Matrices. ASAIO Transactions, 1986, 32, 587-590.	0.2	17
123	Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. American Heart Journal, 1996, 131, 211-218.	2.7	17
124	Intracellular signaling mechanisms associated with CD47 modified surfaces. Biomaterials, 2013, 34, 8640-8649.	11.4	17
125	High reactivity of alkyl sulfides towards epoxides under conditions of collagen fixationâ€”a convenient approach to 2-amino-4-butyrolactones. Biomaterials, 2001, 22, 2501-2506.	11.4	16
126	Porphyrinâ€Based SOD Mimic MnTnBuOEâ€2â€PyP 5+ Inhibits Mechanisms of Aortic Valve Remodeling in Human and Murine Models of Aortic Valve Sclerosis. Journal of the American Heart Association, 2018, 7, e007861.	3.7	16

#	Article	IF	Citations
127	Determinants of the modulated release of antiarrhythmic drugs by iontophoresis through polymer membranes. Macromolecules, 1993, 26, 2264-2272.	4.8	14
128	The efficacy of controlled release D-sotalol-polyurethane epicardial implants for ventricular arrhythmias due to acute ischemia in dogs. Journal of Controlled Release, 1993, 23, 75-85.	9.9	13
129	Gene-based therapies for restenosis. Advanced Drug Delivery Reviews, 1997, 24, 109-120.	13.7	13
130	The effects of the covalent attachment of 3-(4-hydroxy-3,5-di-tert-butylphenyl) propyl amine to glutaraldehyde pretreated bovine pericardium on structural degeneration, oxidative modification, and calcification of rat subdermal implants. Journal of Biomedical Materials Research - Part A, 2015, 103, 2441-2448.	4.0	13
131	Paraffin processing of stented arteries using a postfixation dissolution of metallic and polymeric stents. Cardiovascular Pathology, 2016, 25, 483-488.	1.6	13
132	Ethanol inhibition of porcine bioprosthetic heart valve cusp calcification is enhanced by reduction with sodium borohydride. Journal of Heart Valve Disease, 2004, 13, 487-93.	0.5	13
133	Efficacy of Epicardial Controlled-Release Lidocaine for Ventricular Tachycardia Induced by Rapid Ventricular Pacing in Dogs. Journal of Cardiovascular Pharmacology, 1990, 16, 812-817.	1.9	12
134	Biological stability of polyurethane modified with covalent attachment of di-tert-butyl-phenol. Journal of Biomedical Materials Research - Part A, 2007, 82A, 1004-1011.	4.0	12
135	Prevention of polyurethane oxidative degradation with phenolic antioxidants covalently attached to the hard segments: Structureâ€“function relationships. Journal of Biomedical Materials Research - Part A, 2010, 94A, 751-759.	4.0	12
136	Thymosin beta4 regulation, expression and function in aortic valve interstitial cells. Journal of Heart Valve Disease, 2002, 11, 726-35.	0.5	12
137	Adenoviral vector tethering to metal surfaces via hydrolyzable cross-linkers for the modulation of vector release and transduction. Biomaterials, 2013, 34, 6938-6948.	11.4	11
138	Circulating and tissue matricellular RNA and protein expression in calcific aortic valve disease. Physiological Genomics, 2020, 52, 191-199.	2.3	11
139	Conversion of ouabain-induced ventricular tachycardia in dogs with epicardial lidocaine: pharmacodynamics and functional effects. Pharmaceutical Research, 1990, 07, 28-33.	3.5	10
140	Controlled release implant dosage forms for cardiac arrhythmias: Review and perspectives. Drug Delivery, 1996, 3, 137-142.	5.7	10
141	The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits. Journal of Visualized Experiments, 2014, , .	0.3	10
142	Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis. Heart, 2019, 105, heartjnl-2018-314403.	2.9	10
143	Site-specific gene therapy for cardiovascular disease. Current Opinion in Drug Discovery & Development, 2010, 13, 203-13.	1.9	10
144	Modulated Drug Release Using Iontophoresis Through Heterogeneous Cation-Exchange Membranes. 2. Influence of Cation-Exchanger Content on Membrane Resistance and Characteristic Times. Journal of Pharmaceutical Sciences, 1994, 83, 1482-1494.	3.3	9

#	Article	IF	Citations
145	CD47-dependent molecular mechanisms of blood outgrowth endothelial cell attachment on cholesterol-modified polyurethane. Biomaterials, 2010, 31, 6394-6399.	11.4	9
146	Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers. Journal of Visualized Experiments, 2014, , e51653.	0.3	9
147	Calcification of Cardiac Valve Bioprostheses. , 1985, , 661-668.		9
148	Polymeric drug delivery systems for treatment of cardiovascular calcification, arrhythmias and restenosis. Journal of Controlled Release, 1995, 36, 137-147.	9.9	8
149	Novel Delivery of Antiarrhythmic Agents. Clinical Pharmacokinetics, 1995, 29, 1-5.	3.5	8
150	Synergistic inhibition of calcification of porcine aortic root with preincubation in FeCl3 and ?-amino oleic acid in a rat subdermal model. , 1997, 38, 43-48.		8
151	Model features of a cardiac iontophoretic drug delivery implant. Pharmaceutical Research, 1995, 12, 790-795.	3.5	7
152	Stent-Mediated Gene Delivery for Site-Specific Transgene Administration to the Airway Epithelium and Management of Tracheobronchial Tumors. Respiration, 2014, 88, 406-417.	2.6	7
153	Stability and bioactivity of pepCD47 attachment on stainless steel surfaces. Acta Biomaterialia, 2020, 104, 231-240.	8.3	7
154	Prevention of Acute Inducible Atrial Flutter in Dogs by Using an Ibutilide-Polymer-Coated Pacing Electrode. Journal of Cardiovascular Pharmacology, 1998, 31, 449-455.	1.9	7
155	Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1. Scientific Reports, 2022, 12, 5464.	3.3	7
156	Anchoring of self-assembled plasmid DNA/ anti-DNA antibody/cationic lipid micelles on bisphosphonate-modified stent for cardiovascular gene delivery. International Journal of Nanomedicine, 2013, 8, 1029.	6.7	6
157	Pathological Calcification of Biomaterials. , 2020, , 973-994.		6
158	Model studies of advanced glycation end product modification of heterograft biomaterials: The effects of in vitro glucose, glyoxal, and serum albumin on collagen structure and mechanical properties. Acta Biomaterialia, 2021, 123, 275-285.	8.3	6
159	Polymeric Controlled Release of Cardiovascular Drugs. , 1991, , 231-238.		6
160	Poly-2-methyl-2-oxazolineâ€“modified bioprosthetic heart valve leaflets have enhanced biocompatibility and resist structural degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	6
161	Biomechanical and biologic effects of meniscus stabilization using triglycidyl amine. Journal of Biomedical Materials Research - Part A, 2010, 93A, 235-242.	4.0	4
162	Endovascular Gene Delivery from a Stent Platform: Gene- Eluting Stents. Angiology: Open Access, 2013, 01, .	0.1	4

#	Article	IF	Citations
163	Local release polymeric-controlled immunotherapy of cardiac transplants in rats. Polymers for Advanced Technologies, 1992, 3, 345-350.	3.2	3
164	Pathological Calcification of Biomaterials. , 2013, , 739-754.		3
165	Altered Responsiveness to TGFÎ² and BMP and Increased CD45+ Cell Presence in Mitral Valves Are Unique Features of Ischemic Mitral Regurgitation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2049-2062.	2.4	3
166	Optimizing endothelial cell functionalization for cell therapy of vascular proliferative disease using a direct contact co-culture system. Drug Delivery and Translational Research, 2018, 8, 954-963.	5.8	2
167	Prevention of calcification of glutaraldehydeâ€crosslinked porcine aortic cusps by ethanol preincubation: Mechanistic studies of protein structure and waterâ€“biomaterial relationships. Journal of Biomedical Materials Research Part B, 1998, 40, 577-585.	3.1	2
168	Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants. , 1994, , 259-268.		2
169	Robust Chemical Strategy for Stably Labeling Polyester-Based Nanoparticles with BODIPY Fluorophores. ACS Applied Polymer Materials, 2022, 4, 1196-1206.	4.4	2
170	Site Specific Controlled Release for Cardiovascular Disease: Translational Directions. , 2012, , 445-492.		1
171	Cardiovascular delivery of drugs and biotherapeutics. Drug Delivery and Translational Research, 2018, 8, 865-867.	5.8	1
172	Bioprosthetic Heart Valve Calcification: Clinicopathologic Correlations, Mechanisms, and Prevention. Contemporary Cardiology, 2020, , 183-215.	0.1	1
173	Degradation of Materials in the Biological Environment. , 1996, , 411-453.		1
174	Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization. Journal of Visualized Experiments, 2020, , .	0.3	1
175	Biomaterials-Associated Pathology of Cardiac Valve Prostheses: Clinical Explant Analysis and Studies of Tissue Valve Calcification. Materials Research Society Symposia Proceedings, 1985, 55, 29.	0.1	0
176	Experimental Single-Platform Approach to Enhance the Functionalization of Magnetically Targetable Cells. ACS Applied Bio Materials, 2020, 3, 3914-3922.	4.6	0
177	Posttranslational Control of a Cardiac Ion Channel Transgene In Vivo: Clarithromycin-hMiRP1-Q9E Interactions. Human Gene Therapy, 2005, .	2.7	0
178	Controlled-Release Drug Matrices for Local Immunosuppression of Organ Transplants. Medical Intelligence Unit, 1996, , 161-168.	0.2	0
179	Adeno-Associated Viral Vector Immobilization and Local Delivery from Bare Metal Surfaces. Methods in Molecular Biology, 2022, 2394, 601-616.	0.9	0